Related references
Note: Only part of the references are listed.Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Are we missing the mTOR target in breast cancer?
Stephen R. D. Johnston
BREAST CANCER RESEARCH AND TREATMENT (2011)
The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study
E. J. Macaskill et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Novel Agents and Future Directions for Refractory Breast Cancer
Harold J. Burstein
SEMINARS IN ONCOLOGY (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).
T. Bachelot et al.
CANCER RESEARCH (2010)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor a serine 167 phosphorylation
Rachel L. Yamnik et al.
FEBS LETTERS (2010)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
Rachel L. Yamnik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
M. Beeram et al.
ANNALS OF ONCOLOGY (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: Meta-analysis
Davide Mauri et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer
SRD Johnston
CLINICAL CANCER RESEARCH (2006)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
A Boulay et al.
CLINICAL CANCER RESEARCH (2005)
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation
I Beuvink et al.
CELL (2005)
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity
LA DeGraffenried et al.
CLINICAL CANCER RESEARCH (2004)
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
R Schiff et al.
CLINICAL CANCER RESEARCH (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: Evidence from metastatic subgroups and a test of functional ability
H Mouridsen et al.
ONCOLOGIST (2004)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
被撤回的出版物: Estradiol rapidly activates Akt via the ErbB2 signaling pathway (Retracted Article. See vol 18, pg 2096, 2004)
GE Stoica et al.
MOLECULAR ENDOCRINOLOGY (2003)
被撤回的出版物: Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway (Retracted Article. See vol 24, pg 1964, 2005)
GE Stoica et al.
ONCOGENE (2003)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
JM Nabholtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
